No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Biotechnology
Operating as an investment holding company, 3SBio Inc. specializes in the full lifecycle of biopharmaceutical products within the People's Republic of China, encompassing research, development, manufacturing, marketing, and sales. Its diverse portfolio addresses a range of medical needs. Key therapeutic agents include TPIAO, a recombinant human thrombopoietin for chemotherapy-induced and immune thrombocytopenia; YISAIPU, a tumor necrosis factor for rheumatoid arthritis, ankylosing spondylitis, and psoriasis; and recombinant human erythropoietins EPIAO and SEPO, along with Aiyishu, to combat various forms of anemia. In oncology, Cipterbin is used for HER2-positive metastatic breast cancer in combination with chemotherapy. Intefen, a recombinant human interferon, targets lymphatic or hematopoietic malignancies and viral infections, while Inleusin, a human interleukin-2, treats renal cell carcinoma, melanoma, and thoracic fluid build-up. The company also offers Mandi for male alopecia and alopecia areata; Xenopax to prevent acute rejection post-renal transplant; Byetta for glycemic control in type 2 diabetes patients; and Qiming Keli for retinopathy linked to type 2 diabetes. SPARIN, an injectable low-molecular-weight heparin calcium, serves in the prophylaxis and treatment of deep vein thrombosis, and prevents clotting during hemodialysis. Beyond its core pharmaceutical activities, 3SBio Inc. provides additional services such as trading, project management and consultation, technology, and agricultural support. The company maintains strategic alliances with numerous prominent organizations, including AstraZeneca, Lilly, Toray Industries Inc, Samsung Bioepis, Refuge Biotechnologies, Verseau, TLC, Numab, GenSight, Sensorion, and the Dana–Farber Cancer Institute. Established in 1993, its headquarters are situated in Shenyang, People's Republic of China.
www.3sbio.comNo one on the platform currently holds 1530.HK.
No tracked institution reports a position in 1530.HK as of their last filing.
No one on the platform has traded 1530.HK yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 50.4% | 19.9% | 15.2% | — | — | — |
| Rev. Growth % | 94.3% | 25.9% | ||||
| Profit Margin % | 47.9% | 28.9% | 25.6% | |||
| Free Cash Flow Margin % | 51.6% | 23.6% | 20.8% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $9.8B | -46.6% | $1.03 | $0.94–$1.11 | — | 7 |
| 2027 | $10.2B | +4.3% | $1.09 | $1.06–$1.12 | — | 7 |
| 2028 | $11.4B | +11.6% | $1.27 | $0.74–$1.81 | — | 9 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 4 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-20 | $0.74 | $0.51 | -31.2% |
| 2026-03-30 | $4.02 | $3.23 | -19.7% |
| 2025-08-29 | $0.61 | $0.61 | +0.0% |
| 2025-03-25 | $0.46 | $0.43 | -7.0% |
| 2024-08-22 | $0.47 | $0.48 | +1.8% |
| 2024-03-21 | $0.44 | $0.26 | -41.4% |
| 2023-08-24 | $0.38 | $0.43 | +14.8% |
| 2023-03-22 | $0.41 | $0.41 | +1.1% |
| $74.95 |
| -1.12% |
| $94.9B |
| — |
| 2607.HKShanghai Pharmaceuticals Holding Co., Ltd | $11.02 | -1.08% | $63.9B | — |
| 2617.HKTransThera Sciences (Nanjing). Inc. | $9.65 | +0.84% | $3.8B | — |
Source: Financial Modeling Prep · peers by sector/industry